Treatment of Inflammatory Bowel Disease with Biologics

ISBN-13: 9783319602752 / Angielski / Twarda / 2017 / 335 str.

Adam S. Cheifetz; Joseph D. Feuerstein

Opis

This book is a concise yet comprehensive overview of the use of biologics for the treatment of Crohn's disease and ulcerative colitis. The volume details how best to utilize these medications in order to optimize their efficacy and safety, as well as how to understand, recognize, and treat complications that may arise from using biologics to treat IBD. The text also focuses on new data, novel biologics, and biosimilars of this rapidly expanding field. Written by experts in the field, Treatment of Inflammatory Bowel Disease with Biologics is a valuable resource for gastroenterologists, allied health professionals, fellows, and trainees who treat patients with inflammatory bowel disease.

Spis treści

1. Mechanism of Action and Pharmacokinetics of Biologics

Alan C. Moss

2. Anti-tumor Necrosis Factor Agents in Ulcerative Colitis 

Kindra Clark-Snustad, Ives Hot, Scott Lee

3. Anti-tumor Necrosis Factor Agents in Crohn’s Disease

Byron P. Vaughn

4. Anti-TNF Therapy for Treatment of Extraintestinal Manifestations of Inflammatory Bowel Disease 

Sarah Flier

5. Use of Biologics in the Postoperative Management of Crohn’s Disease

Benjamin H. Click, Miguel Reguiero

6. Biologics in Pregnancy and Breastfeeding

Jill K. J. Gaidos, Sunanda V. Kane

7. Concomitant Use of Immunosuppressive Therapy with Tumor Necrosis Factor (TNF) Antagonists in Inflammatory Bowel Disease

Parambir S. Dulai, Corey A. Siegel

8. Therapeutic Drug Monitoring of Biologic Agents

Frank

I. Scott, Mark T. Osterman

9. Use of Biologics in Crohn’s Disease and Ulcerative Colitis Prior to Surgery and Perioperative Risks

Afrin Kamal, Bret Lashner

10. Cessation of Biologics – Can it be Done?

Hang Hock Shim, Cynthia H. Seow

11. Biologic Therapy in Pediatric Inflammatory Bowel Disease 

Sona Patel, Jennifer Strople

12. Infectious Complications of Biologics

Renée M. Marchioni Beery, Joshua R. Korzenik

13. Tumor Necrosis Factor-Alpha Inhibitors and Risks of Malignancy

Julia Hughes, Millie D. Long

14. Non-infectious and Non-malignant Complications of Biologics 

Raymond Cross

15. Biosimilars in Inflammatory Bowel Disease 2017: State of the Science, State of the Art, State of the Finances

Asher Kornbluth

16.

Anti-Integrin Agents in IBD: Efficacy and Risk of Complications

Jimmy K. Limdi, Francis A. Farraye

17. Novel Agents in Inflammatory Bowel Disease

Fernando Velayos

18. Quality, Safety, and Practical Considerations of Using Biologic Therapies

Gil Melmed

O autorze

Adam S. Cheifetz, MD

Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA

Joseph D. Feuerstein, MD

Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA